SCHEMBL562793

SCHEMBL562793

Oc1nc2cnccc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 3/20 0.44
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
ACHE P22303 3/20 0.38
KDM5A P29375 1/20 0.37
FGFR1 P11362 1/20 0.36
FLT1 P17948 1/20 0.36
KDM4E B2RXH2 5/20 0.36
LDHA P00338 1/20 0.36
EPHX2 P34913 1/20 0.36
FEN1 P39748 1/20 0.36
ALDH1A1 P00352 5/20 0.35
PKN1 Q16512 1/20 0.35
PKN2 Q16513 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
PKM P14618 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 2/20 0.35
METAP2 P50579 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34462940 0.83 SMN1; SMN2 (0.50) DAOKDM4EALDH1A1SMN1; SMN2PKM
SCHEMBL4059259 0.75 NUDT1 (0.55) DAOPDE3BPDE3AACHEKDM4E
SCHEMBL3987647 0.75 PDE3B (0.41) DAOPDE3BPDE3AACHEKDM5A
SCHEMBL17950072 0.75 PDE3B (0.41) DAOPDE3BPDE3AACHEKDM5A
SCHEMBL2143546 0.75 ALDH1A1 (0.44) DAOPDE3BPDE3AACHEKDM4E
SCHEMBL30678618 0.75 NUDT1 (0.55) DAOPDE3BPDE3AACHEKDM4E
SCHEMBL4448533 0.75 ALDH1A1 (0.42) DAOPDE3BPDE3AACHEKDM4E
SCHEMBL5806722 0.75 TDP1 (0.49) DAOPDE3BPDE3AACHENPC1
SCHEMBL7271262 0.74 ALDH1A1 (0.54) KDM4ELDHAEPHX2ALDH1A1PKN1
SCHEMBL9635867 0.72 F7 (0.56) FGFR1FLT1KDM4ELDHAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 DAO 927/4885PDE3B 1960/4885PDE3A 1812/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 DAO 945/4885PDE3B 2137/4885PDE3A 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.